GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells With Squalene Adjuvant

GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells With Squalene Adjuvanthttps://blogs.mercola.com:443/sites/vitalvotes/archive/2020/05/05/gsk-and-sanofi-covid19-vaccine-produced-in-insect-cells-with-squalene-adjuvant.aspxTwo of the world’s largest vaccine manufacturers are using DNA technology, insect cells and a squalene adjuvant, AS03, as the basis to develop a COVID-19 vaccine together. GlaxoSmithKline (GSK) and Sanofi Pasteur are partners in the enterprise,enCommunityServer 2008.5 SP1 (Debug Build: 31106.3070)re: GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells With Squalene Adjuvanthttps://blogs.mercola.com:443/sites/vitalvotes/archive/2020/05/05/gsk-and-sanofi-covid19-vaccine-produced-in-insect-cells-with-squalene-adjuvant.aspx?ShowAllComments=True#9966685/6/2020 7:39:20 AM24451277-a5aa-4add-96dc-64081bfd86fa:996668teardrop<p>It will be very interesting how many of the people who get the vaccine will run to the Vaccine Injury Court to try to get money for their vaccine injury, and how many of these injured will actually be reported in the news.</p>